Retinitis Pigmentosa (Retinitis) – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Retinitis Pigmentosa (Retinitis) – Drugs In Development, 2023’, provides an overview of the Retinitis Pigmentosa (Retinitis) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Retinitis Pigmentosa (Retinitis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Retinitis Pigmentosa (Retinitis) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Retinitis Pigmentosa (Retinitis)
- The report reviews pipeline therapeutics for Retinitis Pigmentosa (Retinitis) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Retinitis Pigmentosa (Retinitis) therapeutics and enlists all their major and minor projects
- The report assesses Retinitis Pigmentosa (Retinitis) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Retinitis Pigmentosa (Retinitis)
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Retinitis Pigmentosa (Retinitis)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Retinitis Pigmentosa (Retinitis) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
4D Molecular Therapeutics IncAAVantgarde Bio Srl
AbbVie Inc
Accuitis Pharmaceuticals Inc
AffaMed Therapeutics US Inc
Alder Therapeutics AB
Aldeyra Therapeutics Inc
Allegro Ophthalmics LLC
Andalusian Public Foundation Progress and Health
Anida Pharma Inc
Ankar Pharma SL
Asan Medical Center
Astellas Pharma Inc
Baylor Scott & White Health
Beacon Therapeutics Ltd
Beijing Chinagene Tech Co Ltd
Beijing SoloBio Genetechnology Company Ltd
Biogen Inc
CalciMedica Inc
Casebia Therapeutics LLP
Cedars-Sinai Medical Center
Celiaz Co Ltd
CellGenTech Inc
CIRC Biosciences Inc
Coave Therapeutics
Columbia University Medical Center
Copernicus Therapeutics Inc
Curative Biotechnology Inc
Daewoong Pharmaceutical Co Ltd
Dompe Farmaceutici SpA
EmendoBio Inc
Endogena Therapeutics Inc
Epicrispr Biotechnologies Inc
Eudora
EyeCure Therapeutics Inc
Eyestem Research Pvt Ltd
Eyevensys SAS
Fondazione Telethon
Frontera Therapeutics Inc
GenSight Biologics SA
Hanmi Pharmaceuticals Co Ltd
HuidaGene Therapeutics Co Ltd
ID Pharma Co Ltd
InFlectis BioScience SAS
InGel Therapeutics Inc
iRegene Therapeutics Co Ltd
IVERIC bio Inc
jCyte Inc
Johns Hopkins University
KALA BIO Inc
King Khaled Eye Specialist Hospital
Kiora Pharmaceuticals Inc
Kubota Vision Inc
Kyoto University
Limnopharma SL
Lineage Cell Therapeutics Inc
Locanabio Inc
MeiraGTx Holdings Plc
MimeTech Srl
Mitochem Therapeutics
LLC
Nacuity Pharmaceuticals Inc
Nanoscope Therapeutics Inc
Nanovector srl
Navega Therapeutics Inc
Novartis AG
Ocugen Inc
Oculogenex Inc
OiDE OptoEye Inc
OliX Pharmaceuticals Inc
ONL Therapeutics Inc
Opsis Therapeutics LLC
OptiKira LLC
Opus Genetics Inc
Oregon Health & Science University
Perceive Biotherapeutics Inc
Prime Medicine Inc
Profarma
Prolindox Inc
ProQR Therapeutics NV
PYC Therapeutics Ltd
Ray Therapeutics Inc
ReNeuron Group Plc
ResQ Biotech
Restore Vision Co Ltd
Ripple therapeutics Corp
Rznomics Inc
Saliogen Therapeutics Inc
SanBio Co Ltd
Spanish National Research Council
SparingVision SAS
Staidson BioPharma Inc
Sumitomo Pharma Co Ltd
SunRegen Healthcare AG
Suzhou Ugenex Therapeutics Ltd Co
Sylentis SAU
Thea Open Innovation SASU
Trinity College Dublin
University of Pennsylvania
University of Tubingen
Variant
VCCT Inc
ViGeneron GmbH
Vision Institute
Wave Life Sciences Ltd
Worphmed Srl
Zhongmou Therapeutics